MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2

Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replica...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 11; no. 1; pp. 5376 - 9
Main Authors Uemura, Kentaro, Sasaki, Michihito, Sanaki, Takao, Toba, Shinsuke, Takahashi, Yoshimasa, Orba, Yasuko, Hall, William W., Maenaka, Katsumi, Sawa, Hirofumi, Sato, Akihiko
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 08.03.2021
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.
AbstractList Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.
Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.
Abstract Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.
ArticleNumber 5376
Author Toba, Shinsuke
Takahashi, Yoshimasa
Sato, Akihiko
Orba, Yasuko
Uemura, Kentaro
Sanaki, Takao
Maenaka, Katsumi
Sawa, Hirofumi
Hall, William W.
Sasaki, Michihito
Author_xml – sequence: 1
  givenname: Kentaro
  surname: Uemura
  fullname: Uemura, Kentaro
  organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University
– sequence: 2
  givenname: Michihito
  surname: Sasaki
  fullname: Sasaki, Michihito
  organization: Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University
– sequence: 3
  givenname: Takao
  surname: Sanaki
  fullname: Sanaki, Takao
  organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University
– sequence: 4
  givenname: Shinsuke
  surname: Toba
  fullname: Toba, Shinsuke
  organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University
– sequence: 5
  givenname: Yoshimasa
  surname: Takahashi
  fullname: Takahashi, Yoshimasa
  organization: Department of Immunology, National Institute of Infectious Diseases
– sequence: 6
  givenname: Yasuko
  surname: Orba
  fullname: Orba, Yasuko
  organization: Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University
– sequence: 7
  givenname: William W.
  surname: Hall
  fullname: Hall, William W.
  organization: International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, National Virus Reference Laboratory, School of Medicine, University College of Dublin, Global Virus Network
– sequence: 8
  givenname: Katsumi
  surname: Maenaka
  fullname: Maenaka, Katsumi
  organization: Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Center for Research and Education On Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Global Station for Biosurfaces and Drug Discovery, Hokkaido University
– sequence: 9
  givenname: Hirofumi
  surname: Sawa
  fullname: Sawa, Hirofumi
  organization: Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, Global Virus Network
– sequence: 10
  givenname: Akihiko
  surname: Sato
  fullname: Sato, Akihiko
  email: akihiko.sato@shionogi.co.jp
  organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33686154$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAUhSNUREvpC7BAlth0E4h_YjsbpFFUSqUipBbYWo5zk3qUsQfbM2Levp6mhbaLemPLPufTudf3bXHgvIOieI-rT7ii8nNkuG5kWRFcSiYlKcWr4ohUrC4JJeTg0fmwOIlxWeVVk4bh5k1xSCmXHNfsqAjfr9oaGZimiMCN1gEE6FHyCP6uA8SIFu0ZQRHCFpCOSKOV72FCcRcTrNDgA0o3gHobjd9C2CE_IO2S3dqgMzLpMEKybkTXi6vrsvW_S_KueD3kNzi534-LX1_Pfrbfyssf5xft4rI0nNFUdlRXbBC6oZJ0vawo6SgFgQctTScorgWnTFZ93euha3qMa1NzwJprYLQxjB4XFzO393qp1sGudNgpr626u_BhVDokayZQpBMmE4ZBC846RiTFFKjAUkrasR5n1peZtd50K-gNuJTrewJ9-uLsjRr9VomGVZySDDi9BwT_ZwMxqVVuWW67duA3URHW5EIlrnmWfnwmXfpNcLlVe5UUDWdkn-jD40T_ojx8bRbIWWCCjzHAoIxNOlm_D2gnhSu1HyQ1D5LKg6TuBkmJbCXPrA_0F010NsUsdiOE_7FfcN0CksPZAg
CitedBy_id crossref_primary_10_3390_ijms222413202
crossref_primary_10_1126_scitranslmed_abq4064
crossref_primary_10_1016_j_ebiom_2023_104950
crossref_primary_10_1038_s41467_023_39341_4
crossref_primary_10_1016_j_isci_2023_106634
crossref_primary_10_1371_journal_pone_0307154
crossref_primary_10_1016_j_jinorgbio_2022_111805
crossref_primary_10_1038_s41598_024_83633_8
crossref_primary_10_3389_fmicb_2022_721103
crossref_primary_10_3390_biomedicines10092123
crossref_primary_10_1016_j_antiviral_2022_105342
crossref_primary_10_3390_biomedicines11061658
crossref_primary_10_1021_acs_jmedchem_2c01081
crossref_primary_10_1016_j_bbrc_2021_09_015
crossref_primary_10_4274_atfm_galenos_2024_68095
crossref_primary_10_7554_eLife_90316_3
crossref_primary_10_1007_s10787_025_01650_z
crossref_primary_10_1021_acsomega_3c10484
crossref_primary_10_1007_s00018_024_05370_5
crossref_primary_10_1016_j_isci_2021_103120
crossref_primary_10_7554_eLife_90316
crossref_primary_10_3390_ijms222111739
Cites_doi 10.1016/j.antiviral.2019.104541
10.1016/j.jim.2012.12.010
10.1038/s41564-020-0695-z
10.1128/JVI.01890-13
10.1074/jbc.RA120.013679
10.1128/JVI.79.15.9470-9479.2005
10.1021/acs.jmedchem.7b00734
10.1038/s41586-020-2012-7
10.1371/journal.ppat.1004166
10.1126/science.1110656
10.1038/d41573-020-00016-0
10.1016/S0140-6736(20)30251-8
10.1099/vir.0.81749-0
10.1128/JVI.79.6.3846-3850.2005
10.1073/pnas.2002589117
10.1038/s41586-020-2577-1
10.1056/NEJMoa030781
10.1038/s41422-020-0282-0
10.1073/pnas.1407087111
10.1038/nature02145
10.3390/biom9110696
10.1016/j.cell.2020.02.052
10.1038/s41423-020-0400-4
10.1038/s41467-020-15562-9
10.1016/j.celrep.2020.107940
10.1056/NEJMoa2007016
10.1073/pnas.2003138117
10.1016/S2666-5247(20)30004-5
10.1016/j.antiviral.2017.09.004
10.1099/jgv.0.001453
10.1128/JVI.00094-12
10.1073/pnas.1811345115
10.1016/j.antiviral.2020.104786
10.1101/2020.04.14.039925
10.7883/yoken.JJID.2005.88
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-021-84882-7
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals - May need to register for free articles
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Publicly Available Content Database
CrossRef
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature Open Access Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 9
ExternalDocumentID oai_doaj_org_article_2b7cd11ffa764b428313e3718883b4d1
PMC7940632
33686154
10_1038_s41598_021_84882_7
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Japan Agency for Medical Research and Development
  grantid: JP20wm0225003
  funderid: http://dx.doi.org/10.13039/100009619
– fundername: Japan Agency for Medical Research and Development
  grantid: JP20wm0225003
– fundername: ;
  grantid: JP20wm0225003
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
COVID
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c643t-b3a04f7a9382bd8032b33e71fa8cb7315763480d5dafb9d115c56e1a6ae439c43
IEDL.DBID 7X7
ISSN 2045-2322
IngestDate Tue Aug 26 23:45:37 EDT 2025
Thu Aug 21 13:51:10 EDT 2025
Fri Jul 11 00:51:05 EDT 2025
Wed Aug 13 07:16:35 EDT 2025
Thu Apr 03 06:56:41 EDT 2025
Tue Jul 01 01:07:38 EDT 2025
Thu Apr 24 23:01:43 EDT 2025
Fri Feb 21 02:39:16 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c643t-b3a04f7a9382bd8032b33e71fa8cb7315763480d5dafb9d115c56e1a6ae439c43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2498796421?pq-origsite=%requestingapplication%
PMID 33686154
PQID 2498796421
PQPubID 2041939
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_2b7cd11ffa764b428313e3718883b4d1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7940632
proquest_miscellaneous_2499388156
proquest_journals_2498796421
pubmed_primary_33686154
crossref_citationtrail_10_1038_s41598_021_84882_7
crossref_primary_10_1038_s41598_021_84882_7
springer_journals_10_1038_s41598_021_84882_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-03-08
PublicationDateYYYYMMDD 2021-03-08
PublicationDate_xml – month: 03
  year: 2021
  text: 2021-03-08
  day: 08
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Ou (CR17) 2020; 11
Zheng (CR14) 2018; 92
Chandran (CR28) 2005; 308
Lu (CR1) 2020; 395
Gorbalenya (CR2) 2020; 5
Hoffmann (CR11) 2020; 181
Brown (CR29) 2019; 169
CR34
Tai (CR15) 2020; 17
Riva (CR9) 2020
Ohnishi (CR38) 2005; 58
Goldhill (CR27) 2018; 115
Li (CR10) 2003; 426
Zhou (CR12) 2020; 579
Tseng (CR21) 2005; 79
Matsuyama (CR24) 2020; 117
Wang (CR25) 2020; 30
Corman (CR37) 2020; 25
Gordon (CR26) 2020; 295
Ogando (CR33) 2020
Mille, Whittaker (CR35) 2014; 111
Ksiazek (CR3) 2003; 348
Mehellou, Rattan, Balzarini (CR31) 2018; 61
Mossel (CR7) 2005; 79
Shang (CR16) 2020; 117
Kawase, Shirato, van der Hoek, Taguchi, Matsuyama (CR13) 2012; 86
Ren (CR22) 2006; 87
Chu (CR6) 2020; 1
Wang (CR18) 2012; 20
Choy (CR32) 2020; 178
Shirato, Kawase, Matsuyama (CR20) 2013; 87
Mumtaz (CR30) 2017; 146
Kim (CR36) 2019; 9
Liao, Sikkema, Wang, Lee (CR23) 2013; 389
Li, De Clercq (CR4) 2020; 19
Pruijssers (CR8) 2020; 32
Lundin (CR19) 2014; 10
Grein (CR5) 2020; 382
K Chandran (84882_CR28) 2005; 308
R Lu (84882_CR1) 2020; 395
K Ohnishi (84882_CR38) 2005; 58
C-TK Tseng (84882_CR21) 2005; 79
AE Gorbalenya (84882_CR2) 2020; 5
AJ Brown (84882_CR29) 2019; 169
JK Mille (84882_CR35) 2014; 111
AJ Pruijssers (84882_CR8) 2020; 32
W Li (84882_CR10) 2003; 426
CJ Gordon (84882_CR26) 2020; 295
Kim (84882_CR36) 2019; 9
Y Mehellou (84882_CR31) 2018; 61
M Hoffmann (84882_CR11) 2020; 181
M Wang (84882_CR25) 2020; 30
J Grein (84882_CR5) 2020; 382
K Shirato (84882_CR20) 2013; 87
S Matsuyama (84882_CR24) 2020; 117
H Chu (84882_CR6) 2020; 1
L Riva (84882_CR9) 2020
K Liao (84882_CR23) 2013; 389
M Kawase (84882_CR13) 2012; 86
N Mumtaz (84882_CR30) 2017; 146
G Li (84882_CR4) 2020; 19
P Zhou (84882_CR12) 2020; 579
J Shang (84882_CR16) 2020; 117
A Lundin (84882_CR19) 2014; 10
Y Zheng (84882_CR14) 2018; 92
DY Wang (84882_CR18) 2012; 20
X Ren (84882_CR22) 2006; 87
DH Goldhill (84882_CR27) 2018; 115
NS Ogando (84882_CR33) 2020
W Tai (84882_CR15) 2020; 17
VM Corman (84882_CR37) 2020; 25
KT Choy (84882_CR32) 2020; 178
EC Mossel (84882_CR7) 2005; 79
84882_CR34
X Ou (84882_CR17) 2020; 11
TG Ksiazek (84882_CR3) 2003; 348
References_xml – volume: 169
  start-page: 104541
  year: 2019
  ident: CR29
  article-title: Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2019.104541
– volume: 389
  start-page: 52
  year: 2013
  end-page: 60
  ident: CR23
  article-title: Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2)
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2012.12.010
– volume: 5
  start-page: 536
  year: 2020
  end-page: 544
  ident: CR2
  article-title: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-0695-z
– volume: 87
  start-page: 12552
  year: 2013
  end-page: 12561
  ident: CR20
  article-title: Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2
  publication-title: J. Virol.
  doi: 10.1128/JVI.01890-13
– volume: 295
  start-page: 6785
  year: 2020
  end-page: 6797
  ident: CR26
  article-title: Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA120.013679
– volume: 79
  start-page: 9470
  year: 2005
  end-page: 9479
  ident: CR21
  article-title: Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized calu-3 lung epithelial cells
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.15.9470-9479.2005
– volume: 61
  start-page: 2211
  year: 2018
  end-page: 2226
  ident: CR31
  article-title: The protide prodrug technology: from the concept to the clinic
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.7b00734
– volume: 579
  start-page: 270
  year: 2020
  end-page: 273
  ident: CR12
  article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– volume: 10
  start-page: e1004166
  year: 2014
  ident: CR19
  article-title: Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle east respiratory syndrome virus
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1004166
– volume: 308
  start-page: 1643
  year: 2005
  end-page: 1645
  ident: CR28
  article-title: Endosomal proteolysis of the ebola virus glycoprotein is necessary for infection
  publication-title: Science
  doi: 10.1126/science.1110656
– volume: 19
  start-page: 149
  year: 2020
  end-page: 150
  ident: CR4
  article-title: Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/d41573-020-00016-0
– volume: 395
  start-page: 565
  year: 2020
  end-page: 574
  ident: CR1
  article-title: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30251-8
– volume: 87
  start-page: 1691
  year: 2006
  end-page: 1695
  ident: CR22
  article-title: Analysis of ACE2 in polarized epithelial cells: Surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus
  publication-title: J. Gen. Virol.
  doi: 10.1099/vir.0.81749-0
– volume: 79
  start-page: 3846
  year: 2005
  end-page: 3850
  ident: CR7
  article-title: Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.6.3846-3850.2005
– volume: 92
  start-page: 1
  year: 2018
  end-page: 14
  ident: CR14
  article-title: Lysosomal proteases are a determinant of coronavirus tropism
  publication-title: J. Virol.
– volume: 117
  start-page: 7001
  year: 2020
  end-page: 7003
  ident: CR24
  article-title: Enhanced isolation of SARS-CoV-2 by TMPRSS2- expressing cells
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.2002589117
– year: 2020
  ident: CR9
  article-title: Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
  publication-title: Nature
  doi: 10.1038/s41586-020-2577-1
– volume: 20
  start-page: 938
  year: 2012
  end-page: 946
  ident: CR18
  article-title: Establishment of a serological panel for in vitro diagnostics of severe acute respiratory syndrome
  publication-title: J. Food Drug Anal.
– volume: 58
  start-page: 88
  year: 2005
  end-page: 94
  ident: CR38
  article-title: Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies
  publication-title: Jpn. J. Infect. Dis.
– volume: 348
  start-page: 1953
  year: 2003
  end-page: 1966
  ident: CR3
  article-title: A novel coronavirus associated with severe acute respiratory syndrome
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa030781
– volume: 30
  start-page: 269
  year: 2020
  end-page: 271
  ident: CR25
  article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0282-0
– volume: 111
  start-page: 15214
  year: 2014
  end-page: 15219
  ident: CR35
  article-title: Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1407087111
– volume: 25
  start-page: 1
  year: 2020
  end-page: 8
  ident: CR37
  article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  publication-title: Eurosurveillance
– volume: 426
  start-page: 450
  year: 2003
  end-page: 454
  ident: CR10
  article-title: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
  publication-title: Nature
  doi: 10.1038/nature02145
– volume: 9
  start-page: 696
  year: 2019
  ident: CR36
  article-title: Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 Infection of MRC-5 human lung cells
  publication-title: Biomolecules
  doi: 10.3390/biom9110696
– volume: 181
  start-page: 271
  year: 2020
  end-page: 280.e8
  ident: CR11
  article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– volume: 17
  start-page: 613
  year: 2020
  end-page: 620
  ident: CR15
  article-title: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-020-0400-4
– volume: 11
  start-page: 1620
  year: 2020
  ident: CR17
  article-title: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15562-9
– volume: 32
  start-page: 107940
  year: 2020
  ident: CR8
  article-title: Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2020.107940
– volume: 382
  start-page: 2327
  year: 2020
  end-page: 2336
  ident: CR5
  article-title: Compassionate use of remdesivir for patients with severe Covid-19
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2007016
– volume: 117
  start-page: 11727
  year: 2020
  end-page: 11734
  ident: CR16
  article-title: Cell entry mechanisms of SARS-CoV-2
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.2003138117
– ident: CR34
– volume: 1
  start-page: e14
  year: 2020
  end-page: e23
  ident: CR6
  article-title: Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study
  publication-title: The Lancet Microbe
  doi: 10.1016/S2666-5247(20)30004-5
– volume: 146
  start-page: 161
  year: 2017
  end-page: 163
  ident: CR30
  article-title: Cell-line dependent antiviral activity of sofosbuvir against Zika virus
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2017.09.004
– year: 2020
  ident: CR33
  article-title: SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology
  publication-title: J. Gen. Virol.
  doi: 10.1099/jgv.0.001453
– volume: 86
  start-page: 6537
  year: 2012
  end-page: 6545
  ident: CR13
  article-title: Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry
  publication-title: J. Virol.
  doi: 10.1128/JVI.00094-12
– volume: 115
  start-page: 11613
  year: 2018
  end-page: 11618
  ident: CR27
  article-title: The mechanism of resistance to favipiravir in influenza
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1811345115
– volume: 178
  start-page: 104786
  year: 2020
  ident: CR32
  article-title: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2020.104786
– volume: 87
  start-page: 1691
  year: 2006
  ident: 84882_CR22
  publication-title: J. Gen. Virol.
  doi: 10.1099/vir.0.81749-0
– volume: 395
  start-page: 565
  year: 2020
  ident: 84882_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30251-8
– volume: 11
  start-page: 1620
  year: 2020
  ident: 84882_CR17
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15562-9
– volume: 25
  start-page: 1
  year: 2020
  ident: 84882_CR37
  publication-title: Eurosurveillance
– volume: 9
  start-page: 696
  year: 2019
  ident: 84882_CR36
  publication-title: Biomolecules
  doi: 10.3390/biom9110696
– volume: 17
  start-page: 613
  year: 2020
  ident: 84882_CR15
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-020-0400-4
– volume: 426
  start-page: 450
  year: 2003
  ident: 84882_CR10
  publication-title: Nature
  doi: 10.1038/nature02145
– volume: 308
  start-page: 1643
  year: 2005
  ident: 84882_CR28
  publication-title: Science
  doi: 10.1126/science.1110656
– volume: 87
  start-page: 12552
  year: 2013
  ident: 84882_CR20
  publication-title: J. Virol.
  doi: 10.1128/JVI.01890-13
– year: 2020
  ident: 84882_CR33
  publication-title: J. Gen. Virol.
  doi: 10.1099/jgv.0.001453
– volume: 117
  start-page: 7001
  year: 2020
  ident: 84882_CR24
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.2002589117
– volume: 115
  start-page: 11613
  year: 2018
  ident: 84882_CR27
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1811345115
– volume: 111
  start-page: 15214
  year: 2014
  ident: 84882_CR35
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1407087111
– volume: 79
  start-page: 9470
  year: 2005
  ident: 84882_CR21
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.15.9470-9479.2005
– volume: 382
  start-page: 2327
  year: 2020
  ident: 84882_CR5
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2007016
– volume: 20
  start-page: 938
  year: 2012
  ident: 84882_CR18
  publication-title: J. Food Drug Anal.
– volume: 295
  start-page: 6785
  year: 2020
  ident: 84882_CR26
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA120.013679
– volume: 92
  start-page: 1
  year: 2018
  ident: 84882_CR14
  publication-title: J. Virol.
– volume: 389
  start-page: 52
  year: 2013
  ident: 84882_CR23
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2012.12.010
– volume: 79
  start-page: 3846
  year: 2005
  ident: 84882_CR7
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.6.3846-3850.2005
– volume: 10
  start-page: e1004166
  year: 2014
  ident: 84882_CR19
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1004166
– volume: 86
  start-page: 6537
  year: 2012
  ident: 84882_CR13
  publication-title: J. Virol.
  doi: 10.1128/JVI.00094-12
– volume: 32
  start-page: 107940
  year: 2020
  ident: 84882_CR8
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2020.107940
– volume: 19
  start-page: 149
  year: 2020
  ident: 84882_CR4
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/d41573-020-00016-0
– ident: 84882_CR34
  doi: 10.1101/2020.04.14.039925
– volume: 348
  start-page: 1953
  year: 2003
  ident: 84882_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa030781
– volume: 178
  start-page: 104786
  year: 2020
  ident: 84882_CR32
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2020.104786
– volume: 5
  start-page: 536
  year: 2020
  ident: 84882_CR2
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-0695-z
– year: 2020
  ident: 84882_CR9
  publication-title: Nature
  doi: 10.1038/s41586-020-2577-1
– volume: 1
  start-page: e14
  year: 2020
  ident: 84882_CR6
  publication-title: The Lancet Microbe
  doi: 10.1016/S2666-5247(20)30004-5
– volume: 61
  start-page: 2211
  year: 2018
  ident: 84882_CR31
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.7b00734
– volume: 58
  start-page: 88
  year: 2005
  ident: 84882_CR38
  publication-title: Jpn. J. Infect. Dis.
  doi: 10.7883/yoken.JJID.2005.88
– volume: 30
  start-page: 269
  year: 2020
  ident: 84882_CR25
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0282-0
– volume: 146
  start-page: 161
  year: 2017
  ident: 84882_CR30
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2017.09.004
– volume: 181
  start-page: 271
  year: 2020
  ident: 84882_CR11
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– volume: 117
  start-page: 11727
  year: 2020
  ident: 84882_CR16
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.2003138117
– volume: 579
  start-page: 270
  year: 2020
  ident: 84882_CR12
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– volume: 169
  start-page: 104541
  year: 2019
  ident: 84882_CR29
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2019.104541
SSID ssj0000529419
Score 2.4381807
Snippet Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific...
Abstract Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5376
SubjectTerms 631/326
631/326/596
631/326/596/1296
631/326/596/4130
ACE2
Angiotensin
Angiotensin-converting enzyme 2
Angiotensin-Converting Enzyme 2 - metabolism
Animals
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Antiviral drugs
Cell Engineering
Cell Line
Coronaviruses
COVID-19
COVID-19 - drug therapy
Drug development
Drug Discovery
Humanities and Social Sciences
Humans
Infectivity
Models, Biological
multidisciplinary
Pandemics
Peptidyl-dipeptidase A
Replication
Ribonucleic acid
RNA
RNA viruses
SARS-CoV-2 - drug effects
SARS-CoV-2 - physiology
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Vaccine development
Vero cells
Viral Proteins - biosynthesis
Virus Replication - drug effects
SummonAdditionalLinks – databaseName: Directory of Open Access Journals - May need to register for free articles
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOilNH26SYsKvbUi1sOWfNwuCaGQHpKm5CYkWaKBYpfsBpJ_nxnJu8mmr0uvlmyGeVifpJlvCHlv2iYEgLosgAcx5Y1nToeGYSfGOgmhdS4SO_rSHp6qz2fN2Z1WX5gTVuiBi-L2hNeh5zwlp1vlkR4Mz-3gj2qM9KrPGx9Y8-5spgqrt-gU76YqmVqavQWsVFhNJjgzKsPKjZUoE_b_DmX-mix578Y0L0QHT8jjCUHSWZF8mzyIw1PysPSUvH5GLo6O5w3F8_gFjRPZYOzpcqTxKie90tl8X1A8jI3ULaijuRkOLZTOFDAsBUxIsVoXszuv6ZgoaP8ck4HhkyVzHASjJ7PjEzYfvzHxnJwe7H-dH7KpsQILAECWzEtXq6RdJ43wvaml8FJGzZMzwWvJYQ8ilan7pnfJd6D9JjRt5K51EfBLUPIF2RrGIb4iNHVedSpGg7z2ifemCamNfS1QYVJ2FeErJdswsY5j84sfNt9-S2OLYSwYxmbDWF2RD-t3fhbOjb_O_oS2W89Evuz8ALzITl5k_-VFFdldWd5OQbywsDM1WKkrYPjdehjCD23ohjhe5jmgRaTcqcjL4ihrSaRsDQBGVRG94UIbom6ODOffM8U3_CUBO4qKfFw5261Yf1bF6_-hih3ySGCUYJ6d2SVby4vL-AaA19K_zTF2A_a0JdI
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELbGEBIviN8EBjISb2BIbCd2HhAq1aYJqTxsFO3Nsh17TJoSaDtp_e-5c5KiQtlrbEfO3Tn32b77jpA3uiq9B6jLPFgQk047ZpUvGVZizCPnSqUksdnX6nguv5yVZ3tkLHc0CHC5c2uH9aTmi8v317_Wn2DBf-xTxvWHJTghTBTjBdMyIcZb5DZ4JoUVDWYD3O-5vnkti3rIndk9dMs_JRr_Xdjz3xDKv-5Rk3s6uk_uDbiSTnpDeED2QvuQ3OkrTa4fkcXsZFpSPKVf0jBQEIaGrjoarlMoLJ1MDznFI9pA7ZJamkrk0J7omQKypYAUKebwYsznmnaRgk4uMEQYXtnHk8PE6Onk5JRNu--MPybzo8Nv02M2lFtgHmDJijlhcxmVrYXmrtG54E6IoIpotXdKFLAzEVLnTdnY6OoGoKQvq1DYygZANV6KJ2S_7drwjNBYO1nLEDSy3cei0aWPVWhyjgITos5IMQrZ-IGLHEtiXJp0Jy606RVjQDEmKcaojLzdjPnZM3Hc2Psz6m7TE1m004NucW6GRWm4Ux6-I0arKumQeg7PhMFbay2cbIqMHIyaN6NlGtivaszf5dD8etMMixJ1aNvQXaU-IEUk4snI095QNjMRotIAI2VG1JYJbU11u6W9-JGIv-HfCYiSZ-TdaGx_pvV_UTy_-StekLsc7R_j6vQB2V8trsJLAFor9yqtnt_BcSFH
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyQuiDeBgozEDSwS24mdY1i1qlYqhy5FvVm2Y0OlKkG7W4n-e2acB1ooSFxjO5rMjO0v9sw3hLzVVek9QF3mwYOYdNoxq3zJsBJjHjlXKiWJnX6qTs7l8qK82CN8yoVJQfuJ0jIt01N02IcNbDSYDMYLpmVChXfIAVK1g28fNM1ytZxPVvDuShb1mCGTC33L4J1dKJH134Yw_wyU_O22NG1Cxw_I_RE90maQ9yHZC90jcneoJ3nzmKxPzxYlxbP4DQ0j0WBo6ban4UcKeKXN4ohTPIgN1G6opakQDh3onCngVwp4kGKmLkZ23tA-UtD8JQYCwyuHqHEQjK6asxVb9F8Yf0LOj48-L07YWFSBeQAfW-aEzWVUthaau1bngjshgiqi1d4pUcD_h5A6b8vWRle3ABh9WYXCVjYAdvFSPCX7Xd-F54TG2slahqCR0z4WrS59rEKbc1SYEHVGiknJxo-M41j44sqkm2-hzWAYA4YxyTBGZeTdPOb7wLfxz94f0XZzT-TKTg_69Vcz-o7hTnn4jhitqqRDgjk8-YU9WWvhZFtk5HCyvBkn8MbAX6nGLF0OzW_mZph6aEPbhf469QEtIt1ORp4NjjJLIkSlASzKjKgdF9oRdbelu_yW6L1hhQTcyDPyfnK2X2L9XRUv_q_7S3KP43zAaDp9SPa36-vwCuDV1r0e59NPfocdRQ
  priority: 102
  providerName: Springer Nature
Title MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2
URI https://link.springer.com/article/10.1038/s41598-021-84882-7
https://www.ncbi.nlm.nih.gov/pubmed/33686154
https://www.proquest.com/docview/2498796421
https://www.proquest.com/docview/2499388156
https://pubmed.ncbi.nlm.nih.gov/PMC7940632
https://doaj.org/article/2b7cd11ffa764b428313e3718883b4d1
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdby2AvY9_z1gUN9raJ2pJsyU_DNSklkDKSdeTNSLK8FYbdxSms__3uZCcl--iLDZJsZN1J-vl09ztC3ussdQ6gLnOgQUxabZlRLmWYiTFuOFcqBInNz7OzCzlbpavR4NaPbpXbNTEs1HXn0EZ-DL8JGsMmefLp6ifDrFF4ujqm0LhPDpG6DLVardTOxoKnWDLJx1iZWOjjHvYrjCnjCdMygMu9_SjQ9v8La_7tMvnHuWnYjk4fk0cjjqTFIPgn5J5vn5IHQ2bJm2dkPV-UKUWrfE_9SDnoa7rpqP8VXF9pUU45RZOsp6anhoaUOHQgdqaAZCkgQ4oxu-jjeUO7hoIMLtElGF45-I9Dx-iyWCxZ2X1l_Dm5OJ1-Kc_YmF6BOYAhG2aFiWWjTC40t7WOBbdCeJU0RjurRAJ_IkLquE5r09i8Bujo0swnJjMeUIyT4gU5aLvWvyK0ya3Mpfca2e2bpNapazJfxxwHTIg8Isl2kCs3co9jCowfVTgDF7oaBFOBYKogmEpF5MPumauBeePO1icou11LZM0OBd36WzVOwopb5eA7msaoTFqkmkMbMOzOWgsr6yQiR1vJV-NU7qtbxYvIu101TEKUoWl9dx3awCgi8U5EXg6KsuuJEJkG2CgjovZUaK-r-zXt5fdA9A1rJSBIHpGPW2W77db_h-L13V_xhjzkqP_oR6ePyMFmfe3fArDa2EmYPRNyWBSz5QzuJ9PzzwsoLbNyEowVcJ1L_RsO3iPq
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFLZKEYILYidQwEhwAquJ7cTOAaFhaDWlnR66oLm5seNAJZSUmalg_hS_kfecZKph6a3X2Imct_h99tsIeaWz1DmAusyBBDFptWWFcinDToxxxblSIUlsvJ-NjuWnSTpZI7_6XBgMq-z3xLBRl43DO_JNOCZoTJvkyfuz7wy7RqF3tW-h0YrFrl_8gCPb7N3OR-Dva863t46GI9Z1FWAOrO-cWVHEslJFLjS3pY4Ft0J4lVSFdlaJBAC4kDou07KobF4CYnJp5pMiKzwYbycFfPcauQ6GN8bDnpqo5Z0Oes1kkne5ObHQmzOwj5jDxhOmZQCzK_YvtAn4F7b9O0TzDz9tMH_bd8jtDrfSQStod8mar--RG20ny8V9Mh0fDFOKXoAZ9V2JQ1_SeUP9zxBqSwfDLU7xCtjTYkYLGlrw0LaQNAXkTAGJUswRxpjSBW0qCjw_xRBk-GQbrw4Lo4eDg0M2bD4z_oAcXwnhH5L1uqn9Y0Kr3Mpceq-xmn6VlDp1VebLmCPBhMgjkvRENq6rdY4tN76Z4HMX2rSMMcAYExhjVETeLN85ayt9XDr7A_JuOROrdIcHzfSL6ZTecKsc_EdVFSqTFkvb4Z0zoAGthZVlEpGNnvOm2zpm5kLQI_JyOQxKjzwsat-chzlARSz0E5FHraAsVyJEpgGmyoioFRFaWerqSH36NRQWh70ZECuPyNte2C6W9X9SPLn8L16Qm6Oj8Z7Z29nffUpucdQFjOHTG2R9Pj33zwDUze3zoEmUnFy16v4GSJ1anw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTiBeEN8EBhgJniBqYjuJ84BQ17XaGKumjqG9hdhxYBJKRtsJ-q_x13HnJJ3Kx972GjuRc3e--9n3BfBSxZExCHV9gxLkS620nycm8qkTY1ByniQuSexgEu8ey_cn0ckG_OpyYSisstOJTlEXtaE78j4eExSlTfKwX7ZhEYc743dn333qIEWe1q6dRiMi-3b5A49v87d7O8jrV5yPRx-Hu37bYcA3aIkXvhZ5IMskT4XiulCB4FoIm4RlroxORIhgXEgVFFGRlzotED2ZKLZhHucWDbmRAr97DTYTOhX1YHN7NDmcrm54yIcmw7TN1AmE6s_RWlJGGw99JR20XbOGrmnAv5Du3wGbf3htnTEc34ZbLYplg0bs7sCGre7C9aav5fIezA6mw4iRT2DObFvw0BZsUTP70wXessFwxBldCFuWz1nOXEMe1pSVZoijGeJSRhnDFGG6ZHXJUAJOKSAZP9lEr-PC2NFgeuQP608-vw_HV0L6B9Cr6so-AlamWqbSWkW19cuwUJEpY1sEnAgmROpB2BE5M23lc2rA8S1zHnihsoYxGTImc4zJEg9er945a-p-XDp7m3i3mkk1u92DevYla1VAxnVi8D_KMk9iqanQHd1AIzZQSmhZhB5sdZzPWkUyzy7E3oMXq2FUAcTDvLL1uZuDVKSyPx48bARltRIhYoWgVXqQrInQ2lLXR6rTr67MOGpqxK_cgzedsF0s6_-keHz5XzyHG7htsw97k_0ncJPTVqCAPrUFvcXs3D5FhLfQz9qtxODzVe_e35MAYDo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MRC5+cells+engineered+to+express+ACE2+serve+as+a+model+system+for+the+discovery+of+antivirals+targeting+SARS-CoV-2&rft.jtitle=Scientific+reports&rft.au=Uemura+Kentaro&rft.au=Sasaki+Michihito&rft.au=Sanaki+Takao&rft.au=Toba+Shinsuke&rft.date=2021-03-08&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-021-84882-7&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon